Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study

Overview

Journal Pigment Cell Melanoma Res

Date 2024 Oct 23

PMID 39441554

Authors

Zhonghui Hu

Lu Lu

Jindi Feng

Hongbin Song

Shiyu Zhang

Lu Yang

Yuehua Liu

Tao Wang

Affiliations

Soon will be listed here.

Abstract

Vitiligo is a chronic autoimmune disease, and current treatments for vitiligo have limited efficacy. Janus kinase (JAK) inhibitors could offer new therapeutic options. To evaluate the efficacy and safety of baricitinib, an oral JAK1/2 inhibitor, combined with narrow-band ultraviolet B (NB-UVB) in vitiligo treatment. This prospective, controlled, open-label study included adults with progressive non-segmental vitiligo (NSV). Patients were assigned to combination therapy with baricitinib 2 mg daily and NB-UVB three times a week or NB-UVB alone three times a week (control). The primary endpoint was the proportion of patients achieving 50% or greater improvement from baseline in the total Vitiligo Area Scoring Index (T-VASI50) at week 16. Of the 33 patients (mean age, 34.1 years; 27.3% women) who completed the study, 12 of 17 (70.6%) patients in the combination group and 2 of 16 (12.5%) in the control group had a T-VASI50 response at week 16 (relative risk [RR] = 5.6; 95% CI = 1.5-21.4; p = 0.001). Adverse events were minor, including erythema, mild blister after phototherapy and acne. Combination therapy with low-dose baricitinib and NB-UVB was effective and well tolerated in adults with progressive NSV.

References

Hu Z, Wang T . Beyond skin white spots: Vitiligo and associated comorbidities. Front Med (Lausanne). 2023; 10:1072837. PMC: 9995999. DOI: 10.3389/fmed.2023.1072837. View

Fang W, Lin S, Huang S, Lan C . Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo. Clin Exp Dermatol. 2021; 47(4):782-783. DOI: 10.1111/ced.15070. View

Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel J . British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2021; 186(1):18-29. DOI: 10.1111/bjd.20596. View

Xu Z, Xuan Y, Li Y, Ding Y, Jin S, Xiang L . A prospective observational study of oral abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo. J Am Acad Dermatol. 2024; 91(3):590-592. DOI: 10.1016/j.jaad.2024.05.078. View

Taylor P, Weinblatt M, Burmester G, Rooney T, Witt S, Walls C . Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71(7):1042-1055. PMC: 6618316. DOI: 10.1002/art.40841. View

Elmariah S, Smith J, Merola J . JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. Am J Clin Dermatol. 2022; 23(4):427-431. DOI: 10.1007/s40257-022-00701-3. View

van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen C, Eleftheriadou V . Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. J Invest Dermatol. 2016; 136(5):978-984. DOI: 10.1016/j.jid.2015.12.040. View

Anbar T, Abdel-Rahman A, Hegazy R, El-Khayyat M, Ragaie M . Simultaneous improvement and worsening of vitiligo lesions during the course of NB-UVB phototherapy; vitiligo may not act as one unit. Dermatol Ther. 2016; 30(1). DOI: 10.1111/dth.12420. View

Njoo M, Das P, Bos J, Westerhof W . Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999; 135(4):407-13. DOI: 10.1001/archderm.135.4.407. View

10.

Rosmarin D, Passeron T, Pandya A, Grimes P, Harris J, Desai S . Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022; 387(16):1445-1455. DOI: 10.1056/NEJMoa2118828. View

11.

Craiglow B, King B . Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol. 2015; 151(10):1110-2. DOI: 10.1001/jamadermatol.2015.1520. View

12.

Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y . Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017; 76(6):1054-1060.e1. DOI: 10.1016/j.jaad.2017.02.049. View

13.

Esmat S, El-Tawdy A, Hafez G, Zeid O, Abdel Halim D, Saleh M . Acral lesions of vitiligo: why are they resistant to photochemotherapy?. J Eur Acad Dermatol Venereol. 2011; 26(9):1097-104. DOI: 10.1111/j.1468-3083.2011.04215.x. View

14.

Frisoli M, Essien K, Harris J . Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020; 38:621-648. DOI: 10.1146/annurev-immunol-100919-023531. View

15.

Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G . Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2022; 88(2):395-403. DOI: 10.1016/j.jaad.2022.11.005. View

16.

Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo F, Sturm D . Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021; 22(6):757-774. PMC: 8566637. DOI: 10.1007/s40257-021-00631-6. View

17.

Cunningham K, Rosmarin D . Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. Am J Clin Dermatol. 2023; 24(2):165-186. DOI: 10.1007/s40257-022-00752-6. View

18.

Narayan V, Uitentuis S, Bekkenk M, Wolkerstorfer A . What is successful repigmentation in vitiligo from the point of view of patients?. Br J Dermatol. 2020; 184(1):165-166. PMC: 7818176. DOI: 10.1111/bjd.19422. View

19.

Diotallevi F, Gioacchini H, De Simoni E, Marani A, Candelora M, Paolinelli M . Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. Int J Mol Sci. 2023; 24(5). PMC: 10003418. DOI: 10.3390/ijms24054910. View

20.

Mohammad T, Al-Jamal M, Hamzavi I, Harris J, Leone G, Cabrera R . The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol. 2017; 76(5):879-888. DOI: 10.1016/j.jaad.2016.12.041. View